However, as documented in the literature, IL-2 therapy was found to increase Treg levels (Supplementary Figures 4D, 5C), which are known to suppress anti-tumor immunity and may limit the therapeutic effect of IL-2 (61). The gene discussed is IL2; the disease is neoplasm.